Search Results

Rampart IC Appoints Dr. Eric Secemsky to Medical Advisory Board

February 29, 2024—Rampart IC, an Alabama-based medical device company with radiation shielding solutions to protect catheterization lab teams without the need for traditional lead aprons, announced that Interventional Cardiologist Eric A. Secemsky, MD, will join the company’s Medical Advisory Board. Dr. Secemsky is Director of Vascular Intervention and an interventional cardiologist at Beth Israel Deaconess Medical Center (BIDMC) in Boston, Massachusetts, where he leads the interventional cardiology and vascular research program at the Smith Center for Outcomes Research in Cardiology.

Bivalirudin Compared With Unfractionated Heparin for PCI in STEMI Patients

November 11, 2016—Findings from a study conducted to describe temporal trends and determine the comparative effectiveness of bivalirudin versus unfractionated heparin (UFH) during percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI) was published online ahead of print by Eric A. Secemsky, MD, et al in Journal of the American College of Cardiology (JACC): Cardiovascular Interventions.

AHA/ACC Issue First Acute PE Guidelines With New Clinical Classification System

February 20, 2026—The American College of Cardiology (ACC)/American Heart Association (AHA) Joint Committee on Clinical Practice Guidelines and eight other professional societies released their first joint clinical practice guideline dedicated to the evaluation and management of acute pulmonary embolism (PE) in adults, introducing a new severity-based classification system and comprehensive recommendations spanning diagnosis, treatment, and follow-up care.

ACC and BIDMC Smith Center Collaborate on Renal Denervation Registry

June 10, 2025—The American College of Cardiology (ACC) reported that the Richard A. and Susan F. Smith Center for Outcomes Research at Beth Israel Deaconess Medical Center (BIDMC) in Boston, Massachusetts, and ACC are collaborating on a renal denervation (RDN) module that leverages the Smith Center’s RDN Registry and the ACC CathPCI Registry.

SCAI and National Kidney Foundation Roundtable Outlines Possible Role of Renal Denervation Treatment for Hypertension

August 5, 2021—The Society for Cardiovascular Angiography and Interventions (SCAI) announced the release of a proceedings document outlining the possible role of renal denervation (RDN) as a therapeutic option to complement medical therapy and lifestyle interventions for patients with uncontrolled hypertension.

Medtronic’s Symplicity Spyral Renal Denervation System Gains FDA Approval for Hypertension Treatment

November 17, 2023—Medtronic announced it has received United States Food and Drug Administration (FDA) approval for its Symplicity Spyral Renal Denervation System for the treatment of hypertension.

CathWorks’ FFRangio Compared With Invasive Pressure Wire-Guided PCI in Medicare Outcomes Data Through 2 Years

March 9, 2026—CathWorks announced the presentation of outcomes data from a cohort of more than 4,000 Medicare patients demonstrating that angiography-derived physiology (ADP) using CathWorks FFRangio resulted in similar clinical outcomes compared with invasive pressure wire-guided percutaneous coronary intervention (PCI) through 2 years.

No Excess Mortality Risk Found in Paclitaxel-Coated Devices, Concludes FDA

July 11, 2023—The FDA has determined that the totality of available data and analyses does not support an excess mortality risk for paclitaxel-coated devices, according to the letter issued to health care providers informing them of updated information regarding paclitaxel-coated devices used to treat peripheral arterial disease (PAD).

FDA Advisory Panel Split on Medtronic’s Symplicity Spyral Renal Denervation

August 23, 2023—A Circulatory System Devices Panel met to consider the premarket approval application for the Medtronic Symplicity Spyral renal denervation (RDN) system and advise the FDA regarding approval and optimization of any potential postapproval study.

Endovascular Engineering’s Helo Thrombectomy System for PE Studied in ENGULF

November 7, 2023—Endovascular Engineering, Inc. (E2) announced recently that initial results from its ENGULF study demonstrated successful outcomes among the first 15 patients evaluated in the trial using E2’s Helo thrombectomy system for the treatment of acute submassive pulmonary embolism (PE).